Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Rogers-Evans

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Journal of Medicinal Chemistry|January 5, 2002
Development of a virtual screening method for identification of "frequent hitters" in compound librariesOlivier Roche, Petra Schneider, Jochen Zuegge, et al.
Frontiers in Pharmacology|July 29, 2024
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal modelsUwe Grether, Richard H Foxton, Sabine Gruener, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Journal of Medicinal Chemistry|January 5, 2002
Development of a virtual screening method for identification of "frequent hitters" in compound librariesOlivier Roche, Petra Schneider, Jochen Zuegge, et al.
Frontiers in Pharmacology|July 29, 2024
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal modelsUwe Grether, Richard H Foxton, Sabine Gruener, et al.
Pageof 3